AZNAstraZenecaRunning, no new patients
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 407 (final count)
- Started
- Nov 27, 2018
- Main results expected
- Jun 23, 2024
- Fully finished
- Feb 26, 2027
- Results posted
- Feb 12, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)
Measured over: Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03706690 · record last updated 2026-08-06 · checked 2026-11-09 15:47 UTC